Previous 10 | Next 10 |
home / stock / cslly / cslly news
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...
CSL Limited's top line and bottom line grew by +17% and +45% YoY in 1H FY 2021, which was driven by both non-recurring items and increased sales of influenza vaccines. The company's revenue and earnings growth are expected to slow in FY 2022, with lower-than-expected plasma collection...
CSL Limited (CSLLY): 1H GAAP EPS of $3.98.Revenue of $5.74B (+16.9% Y/Y)Press Release For further details see: CSL Limited reports 1H results
CSL Limited (CSLLY) Q2 2021 Earnings Conference Call February 17, 2021 6:00 PM ET Company Participants Mark Dehring - Vice President, Investor Relations Paul Perreault - Chief Executive Officer John Levy - Interim Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of ...
The following slide deck was published by CSL Limited in conjunction with their 2021 Q2 earnings call. For further details see: CSL Limited 2021 Q2 - Results - Earnings Call Presentation
The Project $1M portfolio got off to a sluggish start and was down approximately 0.3%, still outperforming the S&P 500 which was down nearly 1%. Teladoc, Tencent and Pro Medicus were large contributors, while Mastercard, Visa and Nanosonics suffered. ARK Genomic was a new addi...
Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one me...
When the market is in a phase of rich valuation, it is tempting to broadly identify the market or these stocks as “overvalued”. Making the distinction between stocks deserving high valuations and those that are overvalued is key, particularly in the current market. T...
Lyfebulb Announces Call-to-Action for Submissions to the 2021 Innovation Challenge: Thriving with Transplantation PR Newswire Winning Entry to Receive $25,000 Grant NEW YORK , Jan. 7, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform ...
My Project $1M portfolio, a high growth portfolio designed to outperform the S&P 500 has returned nearly 45% in 2020. Since inception, the portfolio has returned close to 25% annualized versus 14% for the S&P 500. MercadoLibre, Atlassian and Veeva were strong performers fo...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B Canada NewsWire The positive decision from the Canadian Agency for Drugs and Technologies in Health (CADTH) recognizes the im...
CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season PR Newswire CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States . Centers for ...
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...